Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

EGFR mutation + BRAF V600E

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

EGFR mutation + BRAF V600E	Non Small Cell Lung Cancer	EGFR mutation + BRAF V600E	Non Small Cell Lung Cancer	trametinib + osimertinib + dabrafenib Sensitive: C3 – Early Trials trametinib + osimertinib + dabrafenib Sensitive : C3	trametinib + osimertinib + dabrafenib Sensitive: C3 – Early Trials trametinib + osimertinib + dabrafenib Sensitive : C3
EGFR mutation + BRAF V600E	Colorectal Cancer	EGFR mutation + BRAF V600E	Colorectal Cancer	cetuximab + alpelisib + encorafenib Resistant: C3 – Early Trials cetuximab + alpelisib + encorafenib Resistant : C3	cetuximab + alpelisib + encorafenib Resistant: C3 – Early Trials cetuximab + alpelisib + encorafenib Resistant : C3
EGFR mutation + BRAF V600E	Colorectal Cancer	EGFR mutation + BRAF V600E	Colorectal Cancer	cetuximab + binimetinib + encorafenib Resistant: C3 – Early Trials cetuximab + binimetinib + encorafenib Resistant : C3	cetuximab + binimetinib + encorafenib Resistant: C3 – Early Trials cetuximab + binimetinib + encorafenib Resistant : C3
EGFR mutation + BRAF V600E	Colorectal Cancer	EGFR mutation + BRAF V600E	Colorectal Cancer	cetuximab + encorafenib Resistant: C3 – Early Trials cetuximab + encorafenib Resistant : C3	cetuximab + encorafenib Resistant: C3 – Early Trials cetuximab + encorafenib Resistant : C3
EGFR mutation + BRAF V600E	Lung Adenocarcinoma	EGFR mutation + BRAF V600E	Lung Adenocarcinoma	trametinib + erlotinib Sensitive: D – Preclinical trametinib + erlotinib Sensitive : D	trametinib + erlotinib Sensitive: D – Preclinical trametinib + erlotinib Sensitive : D
EGFR mutation + BRAF V600E	Lung Adenocarcinoma	EGFR mutation + BRAF V600E	Lung Adenocarcinoma	erlotinib Resistant: D – Preclinical erlotinib Resistant : D	erlotinib Resistant: D – Preclinical erlotinib Resistant : D